Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRNP | P04156 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | USP2 | O75604 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3722865 | 0.91 | OPRL1 (0.48) | OPRL1CYP3A4CYP2D6TSHRUSP2 | |
| SCHEMBL3668622 | 0.84 | OPRL1 (0.53) | OPRL1CYP3A4CYP2D6TSHRUSP2 | |
| SCHEMBL6526247 | 0.81 | HDAC1 (0.40) | PRNPCYP3A4CYP2D6TSHRCHRM2 | |
| SCHEMBL3723903 | 0.79 | CYP2D6 (0.37) | PRNPCYP3A4CYP2D6TSHRCHRM2 | |
| SCHEMBL6524044 | 0.79 | MGLL (0.40) | PRNPCYP3A4CYP2D6TSHRUSP2 | |
| SCHEMBL29444528 | 0.76 | TSHR (0.45) | CYP3A4CYP2D6TSHRCYP1A2POLB | |
| SCHEMBL6526248 | 0.76 | CYP2D6 (0.41) | PRNPCYP3A4CYP2D6TSHRCHRM2 | |
| SCHEMBL3665994 | 0.74 | DRD4 (0.41) | PRNPOPRL1CYP3A4CYP2D6TSHR | |
| Hydrochloric Acid SCHEMBL3667689 | 0.73 | POLB (0.44) | OPRL1CYP3A4CYP2D6TSHRCYP1A2 | |
| Trifluoroacetic Acid SCHEMBL29663773 | 0.71 | CPB2 (0.54) | OPRL1CPB2CYP3A4CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346805-B2 | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20130072500-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2013-03-21 | — | — | US | disclosed |
| EP-2240483-B1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2013-02-27 | — | — | EP | disclosed |
| US-8324221-B2 | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110053959-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | US | disclosed |
| EP-2240483-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009089454-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053959-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, PIK3CA | PRNP 1766/4885OPRL1 4151/4885CPB2 2151/4885 |
| US-20130072500-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | PIK3CA, AKT1, AKT2 | PRNP 1610/4885OPRL1 3868/4885CPB2 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.